A Study to Evaluate MEDI-524 In Children With Hemodynamically Significant Congenital Heart Disease

NCT00538785 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

1236

Enrollment

INDUSTRY

Sponsor class

Conditions

Congenital Heart Disease

Interventions

BIOLOGICAL: Motavizumab
BIOLOGICAL: Palivizumab

Sponsor

MedImmune LLC